Phase 2
N=16
Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder
Autism Spectrum Disorder
Bottom Line
View on ClinicalTrials.gov: NCT03835117 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Change in Mitochondrial Activity in Study Patients: Citrate Synthase — 40.56; 29.09; 27.41; 37.78 nmoles/min/mg protein
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Wide-spectrum nutritional supplement (Drug); Placebo (Other)
- Age
- Pediatric · 2+ yrs
- Sex
- All
- Sponsor
- Rossignol Medical Center
- Primary completion
- Jul 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mitochondrial Activity in Study Patients: Citrate Synthase |
40.56; 29.09; 27.41; 37.78 | — |
| PRIMARY Change in Mitochondrial Activity in Study Patients: Complex I |
2.88; 3.31; 2.98; 2.86 | — |
| PRIMARY Change in Mitochondrial Activity in Study Patients: Complex II |
0.10; 0.09; 0.09; 0.09 | — |
| PRIMARY Change in Mitochondrial Activity in Study Patients: Complex IV |
0.18; 0.21; 0.22; 0.17 | — |
| SECONDARY Change in the Childhood Autism Rating Scale (CARS) Score |
34.2; 37.2; 30.8; 32.2 | — |
| SECONDARY Change in the Clinical Global Impression Scale (CGI) Score |
4.5; 4.69; 4.31; 4.31 | — |
| SECONDARY Change in the Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CYBOCS-ASD) Score |
12.5; 12.9; 11.3; 11.9 | — |
| SECONDARY Change in the Aberrant Behavior Checklist (ABC) Scores |
77.136; 79.859; 57.293; 73.87 | — |
| SECONDARY Change in the Parent-rated Anxiety Scale for ASD (PRAS-ASD) Score |
30.25; 23.18; 14.625; 26.1 | — |
| SECONDARY Change in the Caregiver Strain Questionnaire (CGSQ) Score |
18.25; 17.625; 11.5; 14.93 | — |
| SECONDARY Change in the Vineland III Caregiver Score |
62.645; 65.199; 69.861; 62.175 | — |
| SECONDARY Evaluate Intervention Safety |
0; 0 | — |
| SECONDARY Examine the Change in Cognitive Ability |
73.627; 65.488; 76.764; 74.143 | — |
Summary
The objective of this study is to evaluate the metabolic effects of a comprehensive wide-spectrum supplement for children with ASD to determine whether it physiologically targets mitochondrial pathways known to be abnormal in children with ASD.The intervention is a commonly used wide-spectrum nutritional supplement, which is theoretically designed to normalize mitochondrial function. The investigators aim to determine if the supplement does have the hypothesized effect on physiology in individuals with ASD. The investigator will enroll up to 50 children, aged 4 to 14 years of age with confirmed ASD and mitochondrial dysfunction, and participation will last 26 weeks.
Eligibility Criteria
Inclusion Criteria
- Weight ≥ 15 kg and ≤ 100kg;
- DSM-5 diagnosis of Autism Spectrum Disorder as established by formal clinical assessment which includes a gold-standard tool such as the Autism Diagnostic Observational Schedule.
- Current Clinical Global Impression Severity score ≥ 4
- Stable educational and therapy plan (one month) with no planned changes in the intensity of treatment for 12 weeks.
- English is spoken in the home and at least one parent is able to read, write and speak English.
- Stable medication (no changes in past 6 weeks and no planned changes for the study duration.
- Electron Transport Chain Complex (I, II, III, IV) or Citrate Synthase Activity which is >= 2.0 Standard Deviation Above or Below Average (outside the normal range)
Exclusion Criteria
- Presence of serious behavioral problems (tantrums, aggression, self-injury) for which another treatment is warranted.
- Current Clinical Global Impression Severity score < 7 (Extremely Ill)
- Significant medical condition by history or by physical examination or lab tests that would be incompatible with the treatment.
- Children taking anticonvulsant medication for seizures or active epilepsy.
- Diagnosis of Mitochondrial Disease
Data sourced from ClinicalTrials.gov (NCT03835117). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.